Back Hepatitis B Hepatitis B Topics HBV Treatment

7. Tenofovir Alafenamide Approved for Hepatitis B

In November the U.S. Food and Drug Administration (FDA) approved tenofovir alafenamide (TAF) for the treatment of hepatitis B, offering a new option that is easier on the bones and kidneys than the older version of tenofovir.

alt

Read more:

AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B

An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well-tolerated, but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, according to a study reported at the AASLD Liver Meeting this month in Boston.

alt

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

Liver Meeting 2016 website

11/20/16

alt

AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus

The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small study presented as a late-breaker at the AASLD Liver Meeting this month in Boston. This combination may potentially enable functional control of hepatitis B if confirmed in larger studies.

alt

Read more:

AASLD 2016: Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus but causes less bone mineral loss, according to a report at the AASLD Liver Meeting this week in Boston. The U.S. Food and Drug Administration last week approved stand-alone TAF for hepatitis B treatment.

alt

Read more: